References
 

1. National Institute of Neurological Disorders and Stroke. Myasthenia gravis fact sheet. 2020.
2. Myasthenia Gravis Foundation of America. Myasthenia gravis infographic. 2018.
3. Conquer Myasthenia Gravis. What is MG? [online] Available at: https://www.myastheniagravis.org/about-mg/what-is-mg/ [Accessed March 2023]   .
4. Punga AR, et al. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):176-188. 
5. Myasthenia Gravis Foundation of America. Foundation Focus, Fall 2016. 2016:11-12
6. McQuillen MP. Ocular myasthenia gravis. Arch Neurol. 1997;54(3):229.
7. Hendricks TM, et al. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study. Am J Ophthalmol. 2019;205:99-105.
8. Muscular Dystrophy Association. Myasthenia Gravis [online] Available at: https://www.mda.org/disease/myasthenia-gravis [Accessed April 2023].
9. Bershad EM, et al. Myasthenia gravis crisis. South Med J. 2008;101(1):63-69.
10. Deenen JCW, et al. The epidemiology of neuromuscular disorders: A comprehensive overview of the literature. J Neuromuscular Dis. 2015;2:73-85.
11. Schneider-Gold C, et al. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1-16.
12. UCB Report, Collaborating for the MG Community (based on social media listening), GL-N-DA-MG-2200006.
13. Stewart SB, et al The prevalence of depression in myasthenia gravis. J Clin Neuromuscul Dis. 2007;8(3):111-15.
14. Law N, et al. The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis. Neurol Ther. 2021;10(2):1103-112